Oxehealth granted regulatory clearances for mental health sleep monitoring

Oxehealth has introduced a groundbreaking medical device that accurately assesses patients' sleep/wake patterns, rivaling the precision of polysomnography. This innovation streamlines healthcare workflows by automatically generating daily reports, empowering clinical staff to make informed decisions with ease. Dr. Michael Geonevese emphasized the significance of this technology in acute mental health settings, where obtaining reliable sleep data has traditionally been challenging due to safety concerns associated with standard polysomnography equipment.

Todd Haedrich, CEO of Oxehealth, announced the launch of an Innovator Program, inviting forward-thinking acute mental health providers to explore the potential of this cutting-edge solution. Oxehealth's commitment to leveraging technology to enhance patient care is evident in its partnerships with half of NHS England's mental health providers and its expansion plans into the US and Europe.

Oxehealth's Oxevision platform, comprising camera-based hardware and FDA-cleared, CE-marked medical devices, revolutionizes inpatient care by improving the observation of patients and enabling timely interventions. This platform not only enhances the quality and safety of care delivery but also facilitates effective care planning, ultimately advancing patient outcomes in acute mental health settings globally.